---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-076267"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:48:37.992899+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Cortexyme appoints Dr. Marwan Noel Sabbagh to Board as Class II director

## Summary
- Dr. Sabbagh appointed Class II director effective March 14, 2022, term expires at 2024 annual meeting.
- Entitled to $35,000 annual retainer under the company's Outside Director Compensation Policy.
- Received initial equity grant of 22,058 nonstatutory stock options vesting in equal annual installments over three years.
- Entered into standard form indemnification agreement with the company.

## SEC filing metadata
- accession: 0001193125-22-076267
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312522076267/0001193125-22-076267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312522076267/d334395d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-076267
- JSON: https://secwatch.observer/filing/0001193125-22-076267.json
- Plain text: https://secwatch.observer/filing/0001193125-22-076267.txt

## Key facts
- Executive change
  Marwan Noel Sabbagh was appointed as Director at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 14, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Cortexyme, Inc. (the “Company”), the Board appointed Marwan Noel Sabbagh, M.D., to serve as a Class II director of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522076267/0001193125-22-076267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.